New Clinical study: Announcing a new important clinical trial for wet AMD. This trial will investigate the safety and efficacy of a new, Ranibizumab sustained delivery platform for patients with wet AMD. This is a Genentech Phase II trial studying three different dosages of Ranibizumab in an ocular implant vs. standard monthly intravitreal injections of Ranibizumab.